Chronobiologically explored effects of Telmisartan.

What Was Tested

Researchers studied Aspirin in this randomized controlled trial publication.

Treatment was administered each day at a different circadian stage, upon awakening, and 3, 6, 9, 12, 15 and 18 hr after awakening.

Each data series was analyzed by single cosinor.

Who Took Part

The abstract describes 20 patients taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Aspirin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Aspirin study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Aspirin group a baseline to be compared against.

In the crossover set-up each of the patients took both Aspirin and the comparison in turn, acting as their own control.

During each stage, the following variables were measured at 3-hr intervals during waking: systolic and diastolic blood pressure, heart rate, ejection fraction, intrarenal resistive index, acceleration time, and serum creatinine.

What Was Measured

At matched treatment times, the MESOR and circadian amplitude of each variable were compared among the three treatments by paired t-tests.

Topics PubMed links to this paper include Angiotensin II Type 1 Receptor Blockers, Aspirin, Benzimidazoles, Benzoates, Blood Pressure, Circadian Rhythm and Cyclooxygenase Inhibitors.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Aspirin in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2005 (Clinical and experimental hypertension (New York, N.Y. : 1993)), a journal based in England.

More context: all human trials.